SCHEMBL74259

SCHEMBL74259

Cc1[c]cccc1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7459931 0.73 ALDH1A1 (0.39)
SCHEMBL19022 0.72
SCHEMBL2972 0.72
SCHEMBL22115865 0.72
SCHEMBL6754033 0.69
SCHEMBL5653014 0.69
SCHEMBL3596578 0.69 CYP3A4 (0.39)
SCHEMBL6607475 0.69 CYP3A4 (0.46)
SCHEMBL15414904 0.69 CYP3A4 (0.39)
SCHEMBL695988 0.69 PDCD1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107974080-B Polyamide moulding compositions and multilayer structures made therefrom EMS专利股份公司 2021-07-20 CN claimed
CN-112881568-A Method for simultaneously determining multiple associated harmful substances in food thermal processing 大连工业大学 2021-06-01 CN claimed
EP-3523290-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY Novartis AG (CH) 2019-08-14 EP claimed
EP-3312224-B1 POLYAMIDE MOULDING COMPOSITION AND MULTI-LAYERED STRUCTURE MADE HEREFROM EMS PATENT AG (CH) 2018-12-26 EP claimed
EP-3397756-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY Novartis AG (CH) 2018-11-07 EP claimed
CN-107974080-A Polyamide moulding composition and the sandwich construction being made from it EMS专利股份公司 2018-05-01 CN claimed
EP-3312224-A1 POLYAMIDE MOULDING COMPOSITION AND MULTI-LAYERED STRUCTURE MADE HEREFROM EMS-PATENT AG (CH) 2018-04-25 EP claimed
WO-2018059549-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY NOVARTIS AG (CH) 2018-04-05 WO claimed
WO-2017114497-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY NOVARTIS AG (CH) 2017-07-06 WO claimed
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US claimed
WO-2000069832-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS PHARMACIA CORPORATION (US) 2000-11-23 WO claimed
WO-2000069833-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS PHARMACIA CORPORATION (US) 2000-11-23 WO claimed
WO-2000040558-A1 ASPARTIC PROTEASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-07-13 WO claimed
EP-0827507-B1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM CA LTD (CA) 1999-06-16 EP claimed
EP-0827507-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1998-03-11 EP claimed
US-5705594-A Polyamine crosslinking agent formulation and its preparation BAYER AKTIENGESELLSCHAFT (DE) 1998-01-06 US claimed
EP-0780418-A2 Triamines and a process for their preparation BAYER AG (DE) 1997-06-25 EP claimed
WO-1996031527-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) 1996-10-10 WO claimed
US-5024786-A Having good build up and resistance to staining SANDOZ LTD. (CH) 1991-06-18 US claimed
EP-0314630-A2 Detergent compositions SANDOZ AG (CH) 1989-05-03 EP claimed